CoChat

N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels

Open access

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

Aims: Elevated apolipoprotein C-III (apoC-III) levels are associated with hypertriglyceridaemia and coronary heart disease. AKCEA-APOCIII-LRx is an N-acetyl galactosamine-conjugated antisense oligonucleotide targeted to the liver that selectively inhibits apoC-III protein synthesis. Methods and results: The safety, tolerability, and efficacy of AKCEA-APOCIII-LRx was assessed in a double-blind, placebo-controlled, dose-escalation Phase 1/2a study in healthy volunteers (ages 18–65) with triglyceride levels ≥90 or ≥200 mg/dL. Single-dose cohorts were treated with 10, 30, 60, 90, and 120 mg subcutaneously (sc) and multiple-dose cohorts were treated with 15 and 30 mg weekly sc for 6 weeks or 60 mg every 4 weeks sc for 3 months. In the single-dose cohorts treated with 10, 30, 60, 90, or 120 mg of AKCEA-APOCIII-LRx, median reductions of 0, −42%, −73%, −81%, and −92% in apoC-III, and −12%, −7%, −42%, −73%, and −77% in triglycerides were observed 14 days after dosing. In multiple-dose cohorts of 15 and 30 mg weekly and 60 mg every 4 weeks, median reductions of −66%, −84%, and −89% in apoC-III, and −59%, −73%, and −66% in triglycerides were observed 1 week after the last dose. Significant reductions in total cholesterol, apolipoprotein B, non-high-density lipoprotein cholesterol (HDL-C), very low-density lipoprotein cholesterol, and increases in HDL-C were also observed. AKCEA-APOCIII-LRx was well tolerated with one injection site reaction of mild erythema, and no flu-like reactions, platelet count reductions, liver, or renal safety signals. Conclusion: Treatment of hypertriglyceridaemic subjects with AKCEA-APOCIII-LRx results in a broad improvement in the atherogenic lipid profile with a favourable safety and tolerability profile. ClinicalTrials.gov Identifier: NCT02900027.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehz209

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Figures

Image 1
CC BY-NC · PubMed Central
Figure 1 Single ascending dose cohorts. The graphs display the mean percent change (±SEM) in apoC-III (A), triglycerides (B), apoB (C), and HDL-C (D) in the single dose cohorts. The blue arrowhead represents the timing of the dose. The data were compared between AKCEA-APOCIII-LRx treatments and placebo using one-way analysis of variance or Wilcoxon rank sum test. Subjects were required to have a fasting triglyceride level ≥90 mg/dL for the 10, 30, and 60 mg dose cohorts and ≥200 mg/dL for the 90 and 120 mg cohorts.
Figure 1 Single ascending dose cohorts. The graphs display the mean percent change (±SEM) in apoC-III (A), triglycerides (B), apoB (C), and HDL-C (D) in the single dose cohorts. The blue arrowhead represents the timing of the dose. The data were compared between AKCEA-APOCIII-LRx treatments and placebo using one-way analysis of variance or Wilcoxon rank sum test. Subjects were required to have a fasting triglyceride level ≥90 mg/dL for the 10, 30, and 60 mg dose cohorts and ≥200 mg/dL for the 90 and 120 mg cohorts.CC BY-NC · PubMed Central
Figure 2 Multiple ascending dose cohorts. The graphs display the mean percent change (±SEM) in apoC-III (A), triglycerides (B), apoB (C), and HDL-C (D) in the multiple dose cohorts. The blue arrowhead represents the timing of the doses. The data were compared between AKCEA-APOCIII-LRx treatments and placebo using one-way analysis of variance or Wilcoxon rank sum test. Subjects were required to have a fasting triglyceride level ≥200 mg/dL.
Figure 2 Multiple ascending dose cohorts. The graphs display the mean percent change (±SEM) in apoC-III (A), triglycerides (B), apoB (C), and HDL-C (D) in the multiple dose cohorts. The blue arrowhead represents the timing of the doses. The data were compared between AKCEA-APOCIII-LRx treatments and placebo using one-way analysis of variance or Wilcoxon rank sum test. Subjects were required to have a fasting triglyceride level ≥200 mg/dL.CC BY-NC · PubMed Central
Figure 3 Every 4-week dosing multiple dose cohorts. The graphs display the mean percent change (±SEM) in apoC-III (A), triglycerides (B), apoB (C), and HDL-C (D) in the every 4-week multiple dose cohorts. The blue arrowhead represents the timing of the doses. The data were compared between AKCEA-APOCIII-LRx treatments and placebo using one-way analysis of variance or Wilcoxon rank sum test. Subjects were required to have a fasting triglyceride level ≥200 mg/dL.
Figure 3 Every 4-week dosing multiple dose cohorts. The graphs display the mean percent change (±SEM) in apoC-III (A), triglycerides (B), apoB (C), and HDL-C (D) in the every 4-week multiple dose cohorts. The blue arrowhead represents the timing of the doses. The data were compared between AKCEA-APOCIII-LRx treatments and placebo using one-way analysis of variance or Wilcoxon rank sum test. Subjects were required to have a fasting triglyceride level ≥200 mg/dL.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Research works printed but not linked: 1

  1. Witztum, N Engl J Med

Cited by

See all 244

Metadata

Authors
Alexander, V. J., Xia, S., Hurh, E., Hughes, S. G., O’Dea, L., Geary, R. S., Witztum, J. L., & Tsimikas, S.
Affiliations
  • Ionis Pharmaceuticals (United States) (US)
  • Akcea Therapeutics, 22 Boston Wharf Road, 9th Floor, Boston, MA, USA
  • University of California San Diego (US)
Corresponding author
Tsimikas, Sotirios
Venue
European Heart Journal
Published
2019-04-24
Volume
40
Issue
33
Pages
2785-2796
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2941139188
Cited by
231
References
28
Citations by year
2026: 15 · 2025: 26 · 2024: 37 · 2023: 30 · 2022: 37 · 2021: 44 · 2020: 35 · 2019: 7
FWCI
22.21
Type
journal article
Language
en
Open access
Locations
  • European Heart Journal (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
Funders
Ionis Pharmaceuticals
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
apolipoprotein C-III, antisense oligonucleotides, hypertriglyceridemia, triglycerides, atherogenic lipoproteins, lipid profile, safety and tolerability, dose escalation, HDL cholesterol
MeSH terms
Adolescent, Adult, Aged, Apolipoproteins B, Cholesterol, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Oligonucleotides, RNA, Messenger, Hypertriglyceridemia, Treatment Outcome, Atherosclerosis, Apolipoprotein C-III, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels. https://app.cochat.ai/papers/10.1093/eurheartj/ehz209
The paper
Alexander, V. J., Xia, S., Hurh, E., Hughes, S. G., O’Dea, L., Geary, R. S., Witztum, J. L., & Tsimikas, S. (2019). N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels. European Heart Journal. https://doi.org/10.1093/eurheartj/ehz209

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.